<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632992</url>
  </required_header>
  <id_info>
    <org_study_id>ML42439</org_study_id>
    <nct_id>NCT04632992</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response</brief_title>
  <acronym>MyTACTIC</acronym>
  <official_title>MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to&#xD;
      evaluate the safety and efficacy of targeted therapies as single agents or in rational,&#xD;
      specified combinations in participants with advanced unresectable or metastatic solid tumors&#xD;
      determined to harbor specific biomarkers.&#xD;
&#xD;
      Patients will be enrolled based on local testing performed at a Clinical Laboratory&#xD;
      Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The&#xD;
      multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated&#xD;
      with a drug or drug regimen tailored to their biomarker identified at screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Confirmed Overall Response, as Assessed by the Investigator According to RECIST v1.1 or According to RANO Criteria for Primary CNS Tumors</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>RANO = Response Assessment in Neuro-Oncology; RECIST v1.1 = Response Evaluation Criteria in Solid Tumors, Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival Rate at Every 3 Months, Defined as the Percentage of Participants who are Progression-Free as Determined by the Investigator According to RECIST v1.1 or RANO Criteria</measure>
    <time_frame>At every 3 months until study completion (up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate at Every 3 Months, Defined as the Percentage of Participants who are Alive</measure>
    <time_frame>At every 3 months until study completion (up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)</measure>
    <time_frame>From Baseline until 28 days after the final dose of study drug (up to 4 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Advanced Unresectable or Metastatic Solid Malignancy</condition>
  <arm_group>
    <arm_group_label>Arm A: Entrectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Inavolisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Alectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Ipatasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E: Atezolizumab + Investigator's Choice of Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: Trastuzumab Emtansine + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: PH FDC SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H: PH FDC SC + Investigator's Choice of Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I: Trastuzumab Emtansine + Tucatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm J: Trastuzumab Emtansine + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm K: Ipatasertib + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm L: Ipatasertib + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm M: Ipatasertib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm N: Atezolizumab + Tiragolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm O: Pralsetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.</description>
    <arm_group_label>Arm A: Entrectinib</arm_group_label>
    <other_name>Rozlytrek™</other_name>
    <other_name>RG6268</other_name>
    <other_name>RO7102122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inavolisib</intervention_name>
    <description>Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.</description>
    <arm_group_label>Arm B: Inavolisib</arm_group_label>
    <other_name>GDC-0077</other_name>
    <other_name>RG6114</other_name>
    <other_name>RO7113755</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.</description>
    <arm_group_label>Arm C: Alectinib</arm_group_label>
    <other_name>Alecensa®</other_name>
    <other_name>RG7853</other_name>
    <other_name>RO5424802</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.</description>
    <arm_group_label>Arm D: Ipatasertib</arm_group_label>
    <arm_group_label>Arm K: Ipatasertib + Atezolizumab</arm_group_label>
    <arm_group_label>Arm L: Ipatasertib + Atezolizumab</arm_group_label>
    <arm_group_label>Arm M: Ipatasertib + Paclitaxel</arm_group_label>
    <other_name>GDC-0068</other_name>
    <other_name>RG7440</other_name>
    <other_name>RO5532961</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).</description>
    <arm_group_label>Arm E: Atezolizumab + Investigator's Choice of Chemotherapy</arm_group_label>
    <arm_group_label>Arm F: Trastuzumab Emtansine + Atezolizumab</arm_group_label>
    <arm_group_label>Arm J: Trastuzumab Emtansine + Atezolizumab</arm_group_label>
    <arm_group_label>Arm K: Ipatasertib + Atezolizumab</arm_group_label>
    <arm_group_label>Arm L: Ipatasertib + Atezolizumab</arm_group_label>
    <arm_group_label>Arm N: Atezolizumab + Tiragolumab</arm_group_label>
    <other_name>Tecentriq®</other_name>
    <other_name>RG7446</other_name>
    <other_name>RO5541267</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Emtansine</intervention_name>
    <description>Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Arm F: Trastuzumab Emtansine + Atezolizumab</arm_group_label>
    <arm_group_label>Arm I: Trastuzumab Emtansine + Tucatinib</arm_group_label>
    <arm_group_label>Arm J: Trastuzumab Emtansine + Atezolizumab</arm_group_label>
    <other_name>Kadcyla®</other_name>
    <other_name>RG3502</other_name>
    <other_name>RO5304020</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf</intervention_name>
    <description>PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.</description>
    <arm_group_label>Arm G: PH FDC SC</arm_group_label>
    <arm_group_label>Arm H: PH FDC SC + Investigator's Choice of Chemotherapy</arm_group_label>
    <other_name>PHESGO™</other_name>
    <other_name>PH FDC SC</other_name>
    <other_name>Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously</other_name>
    <other_name>RG6264</other_name>
    <other_name>RO7198574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.</description>
    <arm_group_label>Arm I: Trastuzumab Emtansine + Tucatinib</arm_group_label>
    <other_name>Tukysa™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigator's Choice of Chemotherapy</intervention_name>
    <description>Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.</description>
    <arm_group_label>Arm E: Atezolizumab + Investigator's Choice of Chemotherapy</arm_group_label>
    <arm_group_label>Arm H: PH FDC SC + Investigator's Choice of Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.</description>
    <arm_group_label>Arm M: Ipatasertib + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Arm N: Atezolizumab + Tiragolumab</arm_group_label>
    <other_name>RG6058</other_name>
    <other_name>RO7092284</other_name>
    <other_name>MTIG7192A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralsetinib</intervention_name>
    <description>Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.</description>
    <arm_group_label>Arm O: Pralsetinib</arm_group_label>
    <other_name>GAVRETO™</other_name>
    <other_name>RG6396</other_name>
    <other_name>RO7499790</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of advanced unresectable or&#xD;
             metastatic solid malignancy&#xD;
&#xD;
          -  Positive biomarker results from a Clinical Laboratory Improvement Amendments&#xD;
             (CLIA)-certified or equivalently accredited diagnostic laboratory and availability of&#xD;
             a full report of the testing results. This may be from a tissue or blood sample.&#xD;
&#xD;
          -  Evaluable or measurable disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2&#xD;
&#xD;
          -  Life expectancy ≥8 weeks&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, as defined in the protocol, obtained&#xD;
             within 14 days prior to initiation of study treatment&#xD;
&#xD;
          -  Agrees to take measures to prevent pregnancy in the patient or partner&#xD;
&#xD;
          -  In addition to the general inclusion criteria above, there are treatment-specific&#xD;
             inclusion criteria that apply for each respective treatment arm (as detailed in the&#xD;
             protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current participation or enrollment in another therapeutic clinical trial&#xD;
&#xD;
          -  Symptomatic or actively progressing CNS metastases (asymptomatic patients with treated&#xD;
             or untreated CNS metastases may be eligible, provided all protocol-defined criteria&#xD;
             are met)&#xD;
&#xD;
          -  History of leptomeningeal disease, unless noted otherwise for a specific treatment arm&#xD;
             of the study&#xD;
&#xD;
          -  Wide field radiotherapy within 14 days prior to start of study treatment&#xD;
&#xD;
          -  Stereotactic radiosurgery within 7 days prior to start of study treatment&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment, including, but&#xD;
             not limited to, hospitalization for complications of infections, or any active&#xD;
             infection that, in the opinion of the investigator, could impact patient safety&#xD;
&#xD;
          -  Receipt of any anticancer drug/biologic or investigational treatment 21 days prior to&#xD;
             Cycle 1, Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle&#xD;
             1, Day 1 (androgen blockage may be continued for male patients with prostate cancer)&#xD;
&#xD;
          -  Known HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV) infection with status&#xD;
             outside of study-allowed criteria&#xD;
&#xD;
          -  History of or concurrent serious medical condition or abnormality in clinical&#xD;
             laboratory tests that precludes the patient's safe participation in and completion of&#xD;
             the study or confounds the ability to interpret data from the study&#xD;
&#xD;
          -  History of malignancy other than disease under study within 3 years prior to&#xD;
             screening, with the exception of malignancies with a negligible risk of metastasis or&#xD;
             death&#xD;
&#xD;
          -  Incomplete recovery from any surgery prior to the start of study treatment that would&#xD;
             interfere with the determination of safety or efficacy of study treatment&#xD;
&#xD;
          -  Major surgical procedure, other than for diagnosis, or significant traumatic injury&#xD;
             within 4 weeks prior to initiation of study treatment, or anticipation of need for a&#xD;
             major surgical procedure during the study&#xD;
&#xD;
          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or higher), myocardial infarction, or cerebrovascular accident within 3&#xD;
             months prior to enrollment, unstable arrhythmias, or unstable angina&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study&#xD;
&#xD;
          -  In addition to the general exclusion criteria above, there are treatment-specific&#xD;
             exclusion criteria that apply for each respective treatment arm (as detailed in the&#xD;
             protocol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML42439 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham: The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alaska Oncology and Hematology</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Ctr</name>
      <address>
        <city>Oro Valley</city>
        <state>Arizona</state>
        <zip>85755-6216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence - Encinitas</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024-1328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Hematology Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care - Monterey</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Med Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Sacramento Medical Center and Medical Offices</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Jose Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Leandro Medical Center</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - South San Francisco</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Ctr</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology Oncology Specialists</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Permanente - Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360-2740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCRI Florida Cancer Specialists South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - EAST - SCRI - PPDS</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705-1400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - NORTH - SCRI - PPDS</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705-1400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - PAN - SCRI - PPDS</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Luke's Cancer Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Hospital - Baltimore - Hunt - PPDS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229-5201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology Columbia - USOR</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Louis Cancer Care LLP</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frontier Cancer Center and Blood Institute</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Cancer Center</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510-2496</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Hematology Oncology Associates LLC</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724-3009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Astera Cancer Care East Brunswick</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastchester Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Park Hematology and Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028-0506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer &amp; Blood Specialists</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Messino Cancer Centers</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri County Hematologyoncology</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623-3536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Center For Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227-1196</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCRI Tennessee Oncology Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The West Clinic, PC dba West Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders - PPDS</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-4611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mays Cancer Center at UT Health San Antonio MD Anderson Cancer</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University - Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties B</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
    <mesh_term>Pralsetinib</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

